Immunic, Inc. to Present Newly Available Preclinical Data for IMU-935 in Poster Presentation at the 2nd Conference on Molecular Mechanisms of Inflammation in Trondheim, Norway

(PresseBox) ( San Diego, )
.

- Results confirm IMU-935 as a potent inverse agonist of RORgt with an IC50 of 24 nM, leading to potent inhibition of Th17 differentiation while allowing normal thymocyte maturation –

– In addition to its effect on RORgt, IMU-935 is shown to be a DHODH Inhibitor with an IC50 of 240 nM; both mechanisms act synergistically on the reduction of pro-inflammatory cytokine release which would potentially give IMU-935 a broad therapeutic window –

– IMU-935 demonstrates efficacy after oral administration in animal models of colitis and psoriasis –

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, announced that Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, will present today newly available preclinical data confirming IMU-935 as a highly potent inhibitor of both, RORgt and dihydroorotate dehydrogenase (DHODH), which was shown to lead to a strong synergism on the reduction of pro-inflammatory cytokine release. The data also showed that IMU-935 does not affect thymocyte maturation. In previous studies, it was hypothesized that affecting thymocyte development may lead to the risk of developing thymoma. Furthermore, in preclinical animal models of colitis and psoriasis, IMU-935 also demonstrated efficacy after oral administration. Dr. Kohlhof will present the data in a poster presentation at the 2nd Conference on Molecular Mechanisms of Inflammation in Trondheim, Norway, beginning today at 6:00 pm CEST.

An important hallmark of many autoimmune diseases is the imbalance between Th17 cells and regulatory T cells. The key transcription factor for Th17 cell differentiation and IL-17 secretion is the nuclear receptor RORgt, widely believed to be a major switch for the reduction of Th17 cells and cytokines involved in various autoimmune diseases.

The poster, entitled, “Development of IMU-935, an orally available small molecule inhibitor of IL-17 with a unique molecular profile for the treatment of autoimmune diseases,” outlines Immunic’s preclinical models, in which IMU-935 was characterized in different in vitro and cellular assay systems as well as in in vivo disease models, in order to demonstrate its inhibitory capacity on RORgt, DHODH, Th17 differentiation, cytokine secretion and impact on autoimmune diseases, but allowing normal thymocyte maturation.

Results confirm that IMU-935 is a potent inverse agonist of RORgt, with an IC50 (the concentration of drug that inhibits 50 % of the activity of the target) of 24 nM, with a maximum inhibition of approximately 80 %, thereby maintaining a biologically important basal activity at any concentration. As a second and synergistic acting target, IMU-935 was shown to inhibit DHODH with an IC50 of 240 nM. The combined effects lead to a very potent inhibition of the secretion of IL-17A, IL-17F and IFNg, with IC50 concentrations of 3-5 nM tested in human PHA stimulated PBMCs. Th17 differentiation was inhibited with an IC50 of 150 nM. Additionally, the data showed that maintaining a basal activity of RORgt of approximately 20 %, and at the same time synergistically targeting DHODH, effectively leads to inhibition of Th17 differentiation and blocking of IL-17 secretion at very low concentrations, while maintaining normal thymocyte maturation. Previous publications of other research groups had hypothesized that blocking thymocyte maturation may lead to a risk of thymoma development.

IMU-935 also demonstrated activity in a DSS (dextran sulfate sodium) induced colitis model and in an Imiquimod induced psoriasis-like model after oral application of the drug.

“The data are highly encouraging and confirm our belief that IMU-935 is a very potent orally available small molecule inhibitor of the Th17/IL-17 axis with the advantage of not affecting thymocyte maturation, and may, therefore, represent a potential new, best-in-class therapy for certain inflammatory and autoimmune diseases that currently affect millions of patients, globally,” stated Dr. Kohlhof. “We look forward to completing preclinical, IND-enabling studies and remain on track to move IMU-935 into phase 1 double-blind, placebo-controlled, single and multiple ascending dose trials in healthy volunteers later this year. We also plan to extend these studies to assess safety and mechanism-related biomarkers in patients with psoriasis.”
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an service@pressebox.de.